

November 28, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of publication of the third research article in collaboration with Hamamatsu University School of Medicine

- Proof of concept of the potential therapeutic application of next generation SHED for brain cancer –

Tokyo, November 28, 2022 – Kidswell Bio Corporation (KWB) is delighted to announce that the third research articles were published in collaboration with Department of Neurosurgery, Hamamatsu University School of Medicine regarding the innovative research results with the next generation SHED (stem cells from human exfoliated deciduous teeth) in preclinical models of brain cancer.

It is confirmed that SHED has a higher migratory ability of SHED to glioma cells than other cell-derived stem cells. Furthermore, SHED were administrated into a mouse glioma model and accumulated around tumors. SHED could be a potential therapeutic vehicle to deliver genes, which would be novel treatment approaches for cancer.

Publication:

1. Migration Capacity of Stem Cells from Human Exfoliated Deciduous Teeth Towards Glioma.

Yamamoto T, Koizumi S, Oishi T, Horikawa M, Asakawa T, Yamasaki T, Sameshima T, Mitani Y, Namba H, Kurozumi K. J. Integr. Neurosci. 2023, 22(1)

For more details, please refer to the link below.

Manuscript link: <https://www.imrpess.com/journal/JIN/22/1/10.31083/j.jin2201001>

Related press releases:

- [Presentation] R&D Meeting 2022 -Growth Strategies of Cell Therapy (Regenerative Medicine) Business-
https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221109_02.pdf?TabModule605=0
- Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2023
https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221108_02-1.pdf?TabModule583=0
- Announcement of publication of the research articles in collaboration with Hamamatsu University School of Medicine
https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221107_01.pdf?TabModule583=0

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com